It was a bit of a bleak week for the world of biotech, but plenty of story-lines for discussion and analysis. Catch up on all the action with the Biotech Tweets of the Week, curated by @23aloha and @BioDueDiligence.
This week's edition features:
Check it out here: Biotech Tweets of the Week (October 31 - November 4, 2016)
- It's baaack...Valeant returns to the headlines $VRX
- Once-heralded PI3K inhibitors fall from grace $NVGN $INFI $RHHBY
- Pfizer pulls plug on PCSK9 product $PFE $AMGN $SNY $REGN
- Audience grows weary of Gilead's refrain $GILD
- AveXis is this week's "Next Sarepta" with SMA drug update $AVXS
- Palatin claims victory in female sexual dysfunction trials $PTN
- Cempra sinks on liver safety concerns ahead of FDA meeting $CEMP
- Generic drug's turn to enter the pricing spotlight $TEVA $MYL $ENDP
- #ASH16 abstract release $ONCE $BLUE $TRIL $ACHN $KITE $JUNO $QURE $TGTX
- As seen on the stream (the best of the rest, including $AGN $BMRN $LLY $MRGN $SRPT $XBI $IBB
Check it out here: Biotech Tweets of the Week (October 31 - November 4, 2016)
RSS Feed
